| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Neuroblastoma
|
2012
|
NINDS
|
5R01NS055750-05
|
|
Modifiers of Tumor Susceptibility in Murine Neuroblastoma
|
WEISS, WILLIAM
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$331,209
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA116548-07
|
|
Localization and Function of NKT Cells in Neuroblastoma
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$234,457
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA127496-05
|
|
MiRNA Expression in Neuroblastoma
|
STALLINGS, RAYMOND
|
ROYAL COLLEGE OF SURGEONS IN IRELAND
|
IRELAN
|
$184,409
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA148688-02
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
GEORGE, RANI
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$363,125
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA154754-02
|
|
Engineering and Evaluation of Human L-Methionase for Cancer Therapy
|
GEORGIOU, GEORGE
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$430,276
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA138466-03
|
|
Intermittent hypoxia on the progression of neuroblastoma
|
MOHANAM, SANJEEVA
|
UNIVERSITY OF ILLINOIS
|
IL
|
$316,002
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA124709-05
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
MARIS, JOHN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$602,864
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA124644-05
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$324,053
|
|
Neuroblastoma
|
2012
|
NCI
|
1R01CA164132-01
|
|
Predicting toxicity and success of anti-GD2 immunotherapy of neuroblastoma
|
YU, ALICE
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$321,366
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA039771-24
|
|
Molecular Genetic Analysis of Human Neuroblastoma
|
BRODEUR, GARRETT
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$377,150
|
|
Neuroblastoma
|
2012
|
NIGMS
|
5R01GM072611-07
|
|
Statistical Methods for Ultrahigh-dimensional Biomedical Data
|
FAN, JIANQING
|
PRINCETON UNIVERSITY
|
NJ
|
$266,915
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA142636-03
|
|
Improving T-cell therapies for neuroblastoma
|
DOTTI, GIANPIETRO
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$377,399
|
|
Neuroblastoma
|
2012
|
NINDS
|
5R01NS072420-02
|
|
DUSP26: A Novel Therapeutic Target in Neuroblastoma
|
YANG, JIANHUA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$342,344
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA147792-03
|
|
Combination therapy to inhibit neuroblastoma growth
|
RAO, JASTI
|
UNIVERSITY OF ILLINOIS
|
IL
|
$355,503
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA094194-10
|
|
Trk Expression and Inhibition in Human Neuroblastomas
|
BRODEUR, GARRETT
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$366,503
|
|
Neuroblastoma
|
2012
|
NIGMS
|
5R01GM046993-18
|
|
Molecular Genetics of Sensory Organ Development
|
POSAKONY, JAMES
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$302,605
|
|
Neuroblastoma
|
2012
|
NCI
|
5R44CA153561-03
|
|
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect
|
SCHOLZ, WOLFGANG
|
MABVAX THERAPEUTICS, INC.
|
CA
|
$854,905
|
|
Neuroblastoma
|
2012
|
NCI
|
1R43CA159883-01A1
|
|
Reverse ChIP: Sequence-specific extraction of DNA-bound histones for analysis of
|
DAPPRICH, JOHANNES
|
GENERATION BIOTECH, LLC
|
NJ
|
$295,222
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA032685-28
|
|
Clinical Development of HU14.18-IL2 Targeted Therapy
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$311,465
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA140198-04
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
MOSSE, YAEL
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$331,098
|
|
Neuroblastoma
|
2012
|
RMAP
|
1R03DA033980-01A1
|
|
High-throughput screen for specific small-molecule inhibitors of HIF-2A activity
|
KOH, MEI YEE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$39,500
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA136663-03
|
|
Tumor-produced TNF alpha as an inducer of immune resistance and tumor survival
|
LEVITSKAIA, ELENA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$330,091
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA154561-02
|
|
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy
|
SEO, YOUNGHO
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$358,902
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA100030-09
|
|
Optimizing Immunotherapy for Neuroblastoma after BMT
|
JOHNSON, BRYON
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$295,189
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA107263-09
|
|
Integrins and Caspase 8 in Tumor Progression
|
STUPACK, DWAYNE
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$300,934
|
|
Neuroblastoma
|
2012
|
NCI
|
5R21CA161978-02
|
|
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-
|
CHEUNG, NAI-KONG
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$379,518
|
|
Neuroblastoma
|
2012
|
NCI
|
5K08CA136979-04
|
|
Translational Genomics of MicroRNAs in Neuroblastoma
|
COLE, KRISTINA
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$161,773
|
|
Neuroblastoma
|
2012
|
NHLBI
|
5R01HL066310-13
|
|
HIF- 2ALPHA, Hypoxic Gene Regulation, and Angiogenesis
|
SIMON, MARIE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$382,126
|
|
Neuroblastoma
|
2012
|
NIDDK
|
5R01DK061470-10
|
|
Surgical Studies on the Role on Gastrin-releasing Peptide in Neuroblastoma
|
CHUNG, DAI
|
VANDERBILT UNIVERSITY MED CTR
|
TN
|
$332,550
|
|
Neuroblastoma
|
2012
|
NIDCR
|
5F31DE021643-03
|
|
Epigenetic Regulation in Cranial Neural Crest Development
|
HU, NA
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
CA
|
$35,795
|
|
Neuroblastoma
|
2012
|
NCI
|
5K08CA128925-06
|
|
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma
|
GOLDSMITH, KELLY
|
EMORY UNIVERSITY
|
GA
|
$139,320
|
|
Neuroblastoma
|
2012
|
NIGMS
|
5R01GM081670-04
|
|
Mechanism of ECM regulation of actin nucleation during morphogenesis.
|
SOTO, MARTHA
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$290,502
|
|
Neuroblastoma
|
2012
|
NCI
|
5R21CA161537-02
|
|
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology
|
KWON, GLEN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$174,711
|
|
Neuroblastoma
|
2012
|
NINDS
|
5F31NS070559-03
|
|
Functional role of Ascl1 in the developing spinal cord
|
BORROMEO, MARK
|
UNIV OF TX SW MED CTR-DALLAS
|
TX
|
$29,420
|
|
Neuroblastoma
|
2012
|
NCI
|
1F30CA168043-01
|
|
The Role of Stroma-derived Soluble TbetaRIII in Neuroblastoma
|
KNELSON, ERIK
|
DUKE UNIVERSITY
|
NC
|
$47,232
|
|
Neuroblastoma
|
2012
|
NCI
|
1F32CA168274-01
|
|
Quantitative and Spatial Optimization for Designing Cancer Therapeutics
|
ROBINSON-MOSHER, AVRAM
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$52,190
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA067938-14
|
|
The Role of Caspase-8 in Neuroblastoma Tumorigenesis
|
ZAMBETTI, GERARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$383,429
|
|
Neuroblastoma
|
2012
|
NCI
|
5R33CA152809-03
|
|
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$426,711
|
|
Neuroblastoma
|
2012
|
NCI
|
1U01CA168426-01
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$1,211,593
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA127571-05
|
|
MYCN Function in Neuroblastoma
|
IKEGAKI, NAOHIKO
|
UNIVERSITY OF ILLINOIS
|
IL
|
$316,861
|
|
Neuroblastoma
|
2012
|
NINDS
|
5R21NS076969-02
|
|
Nicotinic acetylcholine receptors and neuroblastoma
|
NISHI, RAE
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
VT
|
$228,750
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA132887-05
|
|
Genetic Susceptibility Factors in the Etiology of Neuroblastoma
|
OLSHAN, ANDREW
|
UNIVERSITY OF N CAROLINA AT CHAPEL HILL
|
NC
|
$551,019
|
|
Neuroblastoma
|
2012
|
NCI
|
7U24CA114766-07
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$1,329,162
|
|
Neuroblastoma
|
2012
|
NIGMS
|
1SC3GM102050-01
|
|
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability
|
BOSTANIAN, LEVON
|
XAVIER UNIVERSITY OF LOUISIANA
|
LA
|
$108,471
|
|
Neuroblastoma
|
2012
|
NCI
|
5R01CA158372-02
|
|
Acidic Phospholipid-Selective Treatment for Neuroblastoma
|
QI, XIAOYANG
|
UNIVERSITY OF CINCINNATI
|
OH
|
$330,349
|
|
Neuroblastoma
|
2012
|
NCI
|
1R01CA168903-01
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
CT
|
$358,902
|
|
Neuroblastoma
|
2012
|
NINDS
|
1K08NS079485-01
|
|
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma
|
GUSTAFSON, WILLIAM
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$184,127
|
|
Neuroblastoma
|
2012
|
NCI
|
1R01CA164365-01A1
|
|
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
|
HSU, KATHARINE
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$364,407
|
|
Neuroblastoma
|
2012
|
NCI
|
5P30CA125123-06
|
6455
|
PROGRAM LEADERS---PEDIATRIC CANCER
|
POPLACK, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$14,173
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6820
|
BONE MARROW MICROENVIRONMENT AND NEUROBLASTOMA PROGRESSION
|
DECLERCK, YVES%
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$732,590
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6821
|
NATURAL KILLER CELL BASED IMMUNOTHERAPY
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$189,217
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6822
|
TARGETING MYCN PROTEIN WITH SMALL MOLECULES
|
WEISS, WILLIAM
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$282,760
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6823
|
CLINICAL THERAPY TRIALS
|
MATTHAY, KATHERINE
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$417,566
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6824
|
RESEARCH SUPPORT SERVICES
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$35,327
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6825
|
PATHOLOGY
|
SHIMADA, HIROYUKI
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$37,579
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6826
|
FLOW CYTOMETRY
|
SHEARD, MICHAEL
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$62,669
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6827
|
PRECLINICAL DRUG AND BIOLOGIC TESTING
|
KESHELAVA, NINO
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$91,624
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA081403-13
|
6828
|
BIOSTATISTICS
|
GROSHEN, SUSAN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$157,048
|
|
Neuroblastoma
|
2012
|
NCI
|
5P01CA094237-10
|
0003
|
CHIMERIC T CELLS TARGETING NEUROBLASTOMA
|
BRENNER, MALCOLM
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$267,201
|
|
Neuroblastoma
|
2012
|
NCI
|
5P30CA021765-34
|
9028
|
Development
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$463,855
|
|
Neuroblastoma
|
2012
|
NIBIB
|
1R21EB015040-01A1
|
|
Quantitative Monitoring and Control of Tumor Vascular Permeability in vivo Using
|
SIRSI, SHASHANK
|
UNIVERSITY OF COLORADO AT BOULDER
|
CO
|
$197,908
|
|
Neuroblastoma
|
2012
|
NCI
|
2P30CA082103-14
|
6393
|
Pediatric Malignancies
|
MCCORMICK, FRANK
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$146
|
|
Neuroblastoma
|
2012
|
NCI
|
1R43CA171392-01
|
|
CONSTRUCTION AND TESTING OF A TRIVALENT VACCINE AGAINST NEUROBLASTOMA ADMINISTERE
|
LIVINGSTON, PHILIP
|
MABVAX THERAPEUTICS, INC.
|
CA
|
$149,152
|
|
Neuroblastoma
|
2012
|
NCI
|
1R43CA165899-01A1
|
|
Development of sd-rxRNAs as Therapy for Retinoblastoma and Other Malignancies
|
PAVCO, PAMELA
|
RXI PHARMACEUTICALS CORPORATION
|
MA
|
$292,272
|
|
Neuroblastoma
|
2012
|
NIDCD
|
1R43DC012265-01A1
|
|
Ototoxicity protection with intratympanic steroid implant
|
PIERSTORFF, ERIK
|
O-RAY PHARMA, INC.
|
CA
|
$154,472
|
|
Neuroblastoma
|
2012
|
NCI
|
2R01CA102321-09A1
|
|
Murine Neuroblastoma Models for Preclinical Therapeutics
|
WEISS, WILLIAM
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$257,953
|
|
Neuroblastoma
|
2012
|
NCI
|
3R01CA124644-05S1
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$37,627
|
|
Neuroblastoma
|
2012
|
NCI
|
4R00CA134743-03
|
|
"Oncorequisite" Genes in MYC-mediated Transformation
|
FENG, HUI
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$233,147
|
|
Neuroblastoma
|
2012
|
NCI
|
1K01CA154758-01A1
|
|
MYCN-induced calcium and magnesium signaling regulates Neuroblastoma progression
|
KOOMOA, DANA-LYNN
|
UNIVERSITY OF HAWAII AT HILO
|
HI
|
$134,922
|
|
Neuroblastoma
|
2012
|
NCI
|
2UM1CA097452-11
|
|
Pediatric Phase 1/Pilot Consortium
|
BLANEY, SUSAN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$3,470,000
|
|
Neuroblastoma
|
2012
|
NCI
|
1R43CA173946-01
|
|
Novel anti-ganglioside therapy
|
LARRICK, JAMES
|
PANORAMA RESEARCH, INC.
|
CA
|
$294,070
|
|
Neuroblastoma
|
2012
|
NCI
|
1R43CA174132-01
|
|
Development of transporter targeted platinum drugs for neuroblastoma
|
MAMELOK, RICHARD
|
APRICITY THERAPEUTICS, INC.
|
CA
|
$172,738
|
|
Neuroblastoma
|
2012
|
NIGMS
|
1P20GM103639-01
|
7853
|
TARGETED IMMUNOLIPOSOMAL EF24 AGAINST REL ORCHESTRATED NEUR (Natarajan Aravindan)
|
ARAVINDAN, NATARAJAN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$222,000
|
|
Neuroblastoma
|
2012
|
NIGMS
|
1P20GM103653-01A1
|
7869
|
DSU Sub-Project 2
|
VAN GOLEN, CYNTHIA
|
DELAWARE STATE UNIVERSITY
|
DE
|
$208,866
|
|
Neuroblastoma
|
2012
|
NCI
|
4R00CA151869-03
|
|
Copy number variations (CNVs) in neuroblastoma
|
DISKIN, SHARON
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
PA
|
$249,000
|
|
Neuroblastoma
|
2012
|
NIGMS
|
3F31GM087951-03S1
|
|
Characterizing the Role of Tspan18 in Neural Crest Development
|
FAIRCHILD, CORINNE
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$33,852
|
|
Neuroblastoma
|
2012
|
NCI
|
3U24CA114766-07S1
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$499,863
|
|
Neuroblastoma
|
2012
|
NCI
|
3U24CA114766-07S2
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$1,488,625
|
|
Neuroblastoma
|
2012
|
NIA
|
1ZIAAG000378-05
|
|
Purification of a novel remodeling enzyme
|
PAZIN, MICHAEL
|
NIH
|
|
$31,206
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC010592-09
|
|
Comparative Genomic Hybridization of Neuroblastoma
|
KHAN, JAVED
|
NIH
|
|
$81,575
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC010788-06
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
THIELE-GALETTO, CAROL
|
NIH
|
|
$658,466
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC010789-06
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
THIELE-GALETTO, CAROL
|
NIH
|
|
$658,466
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC010806-06
|
|
Targeting High-risk Neuroblastoma using high through put siRNA screening
|
KHAN, JAVED
|
NIH
|
|
$407,878
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC010958-05
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
DAAR, IRA
|
NIH
|
|
$636,508
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC010998-05
|
|
Identification of Novel Mutations In Pediatric Cancers
|
KHAN, JAVED
|
NIH
|
|
$1,114,868
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC011001-05
|
|
Micro RNA Profiling in Pediatric Cancers
|
KHAN, JAVED
|
NIH
|
|
$135,959
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC011002-05
|
|
BIOINFORMATICS: SYSTEMS BIOLOGY OF NEUROBLASTOMA
|
KHAN, JAVED
|
NIH
|
|
$108,768
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIABC011073-05
|
|
Immunobiology and Immunotherapy of Pediatric Tumors
|
MACKALL, CRYSTAL
|
NIH
|
|
$1,459,080
|
|
Neuroblastoma
|
2012
|
NCI
|
1ZIASC010366-12
|
|
Identification of Genes for Predicting Prognosis in Pediatric Cancers
|
KHAN, JAVED
|
NIH
|
|
$271,919
|
|
Neuroblastoma
|
2012
|
NCI
|
5U54CA163117-02
|
5242
|
Targeting IL-6/IL-6R/STAT3 in EMDR in Neuroblastoma
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$253,723
|
|
Neuroblastoma
|
2012
|
NCI
|
5U54CA163117-02
|
5244
|
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDR
|
YU, HUA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$192,502
|
|
Neuroblastoma
|
2012
|
NCI
|
5U54CA163117-02
|
5245
|
Administrative Core
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL LOS ANGELES
|
CA
|
$126,862
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000140C-5-0-2
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
GLASSER, SALLY
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
CA
|
$113,271
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000025C-7-0-3
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
WARD, KEVIN
|
EMORY UNIVERSITY
|
GA
|
$58,849
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000032C-9-0-3
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
LYNCH, CHARLES
|
UNIVERSITY OF IOWA
|
IA
|
$50,827
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000033C-7-0-4
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
WIGGINS, CHARLES
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
NM
|
$23,070
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000034C-7-0-5
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
WEST, DEE
|
PUBLIC HEALTH INSTITUTE
|
CA
|
$162,786
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000037C-6-0-3
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
GOODMAN, MARC
|
UNIVERSITY OF HAWAII AT MANOA
|
HI
|
$30,917
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000035C-8-0-4
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
DEAPEN, DENNIS
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$119,148
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000029C-9-0-4
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
SCHWARTZ, STEPHEN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$73,114
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000030C-8-0-3
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
CHEN, VIVIEN
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
LA
|
$64,132
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000031C-8-0-4
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
TUCKER, THOMAS
|
UNIVERSITY OF KENTUCKY
|
KY
|
$106,858
|
|
Neuroblastoma
|
2012
|
NCI
|
261201000024C-8-0-3
|
|
Patterns of Care (POC) Quality of Care Dx Yr 2011
|
NO PI IDENTIFIED
|
CONNECTICUT STATE DEPT OF PUBLIC HEALTH
|
CT
|
$38,700
|
